| Dr Amit Bakulesh Mehta, MD | |
|
1365 Wiley Road, Suite 153, Schaumburg, IL 60173-4357 | |
| (847) 519-4701 | |
| (847) 519-4707 |
| Full Name | Dr Amit Bakulesh Mehta |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 21 Years |
| Location | 1365 Wiley Road, Schaumburg, Illinois |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811175003 | NPI | - | NPPES |
| 036120218 | Medicaid | IL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prairieshore Pain Center Pc. | 2163617697 | 4 |
| Global Rehabilitation Clinic, Sc | 3476513672 | 6 |
| Absolute Integrated Health Sc | 7719135854 | 9 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Global Rehabilitation Clinic, Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023101060 PECOS PAC ID: 3476513672 Enrollment ID: O20041012001448 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Absolute Wellness Center Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104145499 PECOS PAC ID: 0143414359 Enrollment ID: O20101102000349 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Prairieshore Pain Center Pc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689905416 PECOS PAC ID: 2163617697 Enrollment ID: O20101110000864 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Absolute Integrated Health Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487921235 PECOS PAC ID: 7719135854 Enrollment ID: O20120917000046 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Pain Management Centers Of Illinois Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609273069 PECOS PAC ID: 5193045334 Enrollment ID: O20150529000119 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Entity Name | Complete Pain Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346807724 PECOS PAC ID: 6507195005 Enrollment ID: O20190909003242 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amit Bakulesh Mehta, MD 1365 Wiley Road, Suite 153, Schaumburg, IL 60173-4357 Ph: (847) 519-4701 | Dr Amit Bakulesh Mehta, MD 1365 Wiley Road, Suite 153, Schaumburg, IL 60173-4357 Ph: (847) 519-4701 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.
Centene Corporation announced today that the Florida Agency for Health Care Administration posted its notice of intent to award a contract for the Managed Medical Assistance program to Centene's Florida subsidiary Sunshine State Health Plan.
Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.
› Verified 5 days ago
Khalid A Sami, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1355 Remington Rd, Suite -h, Schaumburg, IL 60173 Phone: 630-701-9009 | |
Dr. Arpan J Patel, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1365 Wiley Rd, Suite 153, Schaumburg, IL 60173 Phone: 847-519-4701 Fax: 847-519-4707 | |
Wajde Dabah, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 455 S Roselle Rd, Suite 104, Schaumburg, IL 60193 Phone: 847-352-5511 Fax: 847-352-5585 | |
Dr. Kiran Kesava Chekka, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1365 Wiley Rd Ste 153, Schaumburg, IL 60173 Phone: 847-519-4701 Fax: 847-519-4707 | |
Dr. Arkadiusz Grochowski, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 911 N Plum Grove Rd Ste B, Schaumburg, IL 60173 Phone: 630-372-5801 Fax: 630-447-0524 | |
Dr. Amish M Patel, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1365 Wiley Road, Suite 153, Schaumburg, IL 60173 Phone: 847-519-4701 Fax: 847-519-4707 | |
Sunavo Dasgupta, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1365 Wiley Road, Suite 153, Schaumburg, IL 60173 Phone: 847-519-4701 Fax: 847-519-4707 |